Healthcare >> Analyst Interviews >> March 18, 2022

Some Hard-Hit Biotechs Trading at or Below Cash

Raja, Kumaraguru
Dr. Kumaraguru Raja is a Senior Biotech Analyst at Brookline Capital Markets. Previously, he was Vice President, Biotechnology Research at Noble Life Science Partners. He started his equity research career in 2010 as a Senior Associate Analyst on the Citi Research biotechnology team. His expertise includes bottom-up scientific and financial analysis on companies across therapeutic areas and across a spectrum of market capitalizations. He focuses on drug development, intellectual property, FDA and EMA regulations, reimbursement coverage and clinical science. He conducted postdoctoral research at Mayo Clinic on the epigenetic causes of cancer and at Los Angeles Biomedical Research Institute on the molecular mechanisms concerning the role of human bone marrow stem cells in normal and leukemic hematopoiesis. He received a doctoral degree from Bowling Green State University and an MBA from University of California, San Diego. Profile
Word count: 2,148

TWST: Please introduce your coverage with a view to any changes since we spoke last spring?

Dr. Raja: I have added several more companies to